

CLAIMS

What is claimed is:

1. A method of preventing recurrence of a cancer in a mammal, the method comprising administering to the mammal in need thereof a therapeutically effective amount of at least one herbal composition selected from the group consisting of:
 - (a) an herbal extract YIV-906 comprising herbal extracts of *Scutellaria baicalensis* (S), *Glycyrrhiza uralensis* (G), *Paeonia lactiflora* (P), and *Ziziphus jujuba* (Z), a fraction thereof, or any active chemical present in the herbal extract or the fraction thereof, and
 - (b) β -glucuronidase treated YIV-906 (YIV-906GU) or a fraction thereof, or any active chemical present in the YIV-906GU or the fraction thereof;wherein the mammal is further administered an effective amount of at least one immunotherapeutic agent.
2. The method of claim 1, wherein the cancer comprises a solid tumor.
3. The method of any one of claims 1-2, wherein the cancer is at least one selected from the group consisting of melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and pancreatic cancer.
4. The method of any one of claims 1-3, wherein the at least one immunotherapeutic agent is an immune checkpoint inhibitor selected from the group consisting of an anti-PD1, an anti-PD-L1, and an anti-CTLA4 inhibitor.
5. The method of any one of claims 1-4, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of Ipilimumab, Pembrolizumab, Nivolumab, Durvalumab, and Atezolizumab.
6. The method of any one of claims 1-5, wherein the at least one immunotherapeutic agent is an antibody selected from the group consisting of siglec 15 antibody, anti-phosphatidylserine, anti-OX40, anti-CD73, anti-TIM3, anti-CD24, anti-CD47, anti-PD1, anti-PDL1, anti-CTLA4, anti-GITR, anti-CD27, anti-CD28, anti-CD122, anti-TIGIT, anti-VISTA, anti-ICOS, and anti-LAG3.

7. The method of any one of claims 1-6, wherein administering the herbal composition enhances response of the at least one immunotherapeutic agent.
8. The method of any one of claims 1-7, wherein the herbal composition is administered to the mammal orally.
9. The method of any one of claims 1-8, wherein administering the herbal composition promotes stimulator of interferon genes (STING) agonist action.
10. The method of any one of claims 1-9, wherein the herbal composition is administered to the mammal orally in a form selected from the group consisting of a pill, tablet, capsule, soup, tea, concentrate, dragees, liquids, drops, and gelcaps.
11. The method of any one of claims 1-10, wherein the therapeutically effective amount of the herbal composition is about 20 mg/day to about 2000 mg/day.
12. The method of any one of claims 1-11, wherein the therapeutically effective amount of the herbal composition is about 1600 mg/day.
13. The method of any one of claims 1-12, wherein the herbal composition is administered twice daily.
14. The method of any one of claims 1-12, wherein the herbal composition is administered for about one to about two weeks, followed by a suspension of treatment for at least one week.
15. The method of any one of claims 1-14, wherein the herbal composition is administered about 30 mins before administering a chemotherapy or a radiation therapy.
16. The method of claim 15, wherein the administering is continued for about 4 days.

17. The method of any one of claims 1-16, wherein the herbal composition is administered at a time selected from prior to, simultaneously with, and after administration of the one or more immunotherapeutic agent to the mammal.
18. The method of any one of claims 1-17, wherein the mammal is a human.